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Plasminogen/plasmin system is involved in such important processes as thrombosis, inflammation 
and cancer. plasmin and plasminogen mediate their action through plasminogen-binding proteins on the 
cell surface. Lys-plasminogen, but not Glu-plasminogen, shows inhibitory effect on platelet aggregation in-
duced by aDp, collagen and thrombin in preparations of both: platelet-rich plasma and washed platelets. We 
have shown that the kringle domains of Lys-plasminogen mediate interaction of this proenzyme with platelet-
surface proteins. the aim of the work is to study the role of certain kringle domains in the inhibitory effect of 
Lys-plasminogen and to determine possible plasminogen-binding proteins on the platelet surface. all studied 
plasminogen fragments (k1-3, k4 and k5) abolished the inhibitory effect of Lys-plasminogen on platelet ag-
gregation. We observed that k5 was more effective than k1-3 and k4. Biotin-labeled Lys-plasminogen, Glu-
plasminogen and plasminogen fragment K1-3 possessed the highest affinity for actin, whereas the binding of 
biotin-labeled mini-plasminogen and k4 to actin was negligible. We have suggested that inhibitory effect of 
Lys-plasminogen is due to the interaction of kringle domains of this proenzyme with membrane-bound pro-
teins which are exposed on the platelet surface during activation and are involved in thrombus formation.
k e y  w o r d s: plasminogen kringles, platelet aggregation, platelet plasminogen receptors, Lys-plasmino-
gen, actin.
P lasminogen is the pro-enzyme of plasmin, the main enzyme of fibrinolysis. However, plasminogen is also able to bind to cell sur-
face and provide many important reactions including 
proteolytic activity, cell migration and signaling. So, 
plasminogen can play a certain role in such impor-
tant biological processes as inflammation, thrombo-
sis and cancer [1, 2]. The circulating form of plasmi-
nogen is a 92 kDa single-chain zymogen, composed 
of 791 amino acids and divided into seven structural 
domains: N-terminal peptide domain, five kringle 
domains and C-terminal serine protease domain. 
Four of five kringle domains (K1, K2, K4 and K5) 
contain lysine-binding sites (LBS), which mediate 
plasminogen interaction with fibrin clots and cell-
surface receptors. K3-LBS does not bind lysine. It 
was found that K1-LBS is the only LBS for ligand 
binding in circulating plasminogen, whereas all 
other LBS are blocked as they are engaged in intra-
molecular interactions [3]. Compact form of circu-
lating plasminogen is provided by inter-domain in-
teractions between the N-terminal peptide domain 
and K5 and between K3 and K4 organized in a spi-
ral-type domain conformation [4]. Cleavage of the 
N-terminal peptide by plasmin yields a truncated 
form known as Lys-plasminogen, which is present 
in an open conformation. Lys-form of plasminogen 
has some functional peculiarities. It is more read-
ily converted into plasmin [5]. Under physiological 
conditions Lys-plasminogen is not present in circu-
lating blood [6]. However, on the cell surface Lys-
plasminogen is the predominant substrate for plas-
minogen activators [7]. Besides, we have found that 
Lys-plasminogen but not its Glu-form inhibits the 
thrombin- and collagen-induced aggregation in the 
preparation of washed platelets and ADP-induced 
aggregation in preparations of platelet rich plasma. 
As it is known, there are many proteins which are 
exposed on the platelet surface during activation and 
play an important role in platelet aggregation. Some 
of these proteins are able to interact with plasmino-
gen [8, 9]. It was shown that 6-aminohexanoic acid 
abolishes the inhibitory effect of Lys-plasminogen 
that is compatible with the participation of LBS of 
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kringle domains in the inhibitory process [10]. The 
aim of the present work is to study the role of certain 
kringle domains of plasminogen molecule in the in-
hibitory effect of Lys-plasminogen and to determine 
possible plasminogen-binding proteins on the plate-
let surface. 
materials and methods
Human platelets were isolated from blood of 
healthy volunteers (n = 9). Citrate-dextrose solu-
tion was used as an anticoagulant and platelets 
were washed as previously described [10]. Human 
Glu-plasminogen was purified from fresh donor 
plasma with sodium citrate as an anticoagulant and 
Lys-plasminogen was isolated from Cohn fraction 
II-III. Lysine-sepharose chromatography was used 
in both cases [11]. Mini-plasminogen and plasmi-
nogen kringles K1-3 and K4 were obtained accord-
ing to [12] by elastase hydrolyses of plasminogen. 
Fragment K5 was obtained by the limited proteolysis 
of mini-plasminogen with pepsin. K5 isolation was 
carried out by combination of ion-exchange chroma-
tography on DEAE-sephadex A-25 and gel-chroma-
tography on sephadex G-75 [13, 14]. The obtained 
plasminogen forms, kringles K1-3, K4 and K5 were 
homogeneous according to electrophoresis data in 
PAAG [15]. All preparations of plasminogen had no 
spontaneous plasmin activity. 
The influence of plasminogen fragments (K1-3, 
K4, K5) on the inhibitory effect of Lys-plasminogen 
has been studied. Platelet aggregation was measured 
in an aggregometer (SOLAR AT-02, Belorussia). 
All assays were performed within 60-180 minutes 
of platelet collection. The preparation of washed 
platelets (350,000 cells/µl) was set in aggregometer 
cuvette, then platelet suspension was preincubated 
with plasminogen fragments (final concentration 
0.12-1.2 µм) for one minute at 37 °с under stirring, 
then 1.2 µм Lys-plasminogen was added to the re-
action mixture. After 3 minute incubation the plate-
let aggregation was stimulated with thrombin (final 
concentration 1 NIH unit/ml). The preparation of 
washed platelets stimulated by thrombin was used 
as a control. The level of control platelet aggregation 
(the range from 50 to 70%) was taken as 100% value 
in the histograms.
Biotinylation of plasminogen and its fragments 
was carried out as described in [16]. The binding of 
biotin-labeled Glu-, Lys-, mini-plasminogen (Val 
442-Pg) and plasminogen kringles K1-3 and K4 to 
immobilized actin has been studied according to the 
following procedure. Microtiter plate wells (Nunc, 
Denmark) were coated with 100µl of 10 µg/ml ac-
tin in PBS overnight at 4 ºC and then washed five 
times with 0.1 M sodium phosphate buffer (PBS), 
pH 7.4, containing 0.02% tween-20. Wells were 
blocked with 2% BSA in PBS for one hour at 37 ºC. 
Biotinylated Glu-, Lys-, mini-plasminogen and K1-3 
or K4 were added to wells. After two hours of in-
cubation at 37 ºC the wells were washed and phos-
phatase-labeled avidin (100 µl of 0.02 ng/ml avidin 
in PBS) was added to the wells. After one hour of 
incubation at 37 ºC the wells were washed and p-
nitrophenyl phosphate (100 µl of 1 mg/ml in 10% 
diethanolamine buffer, pH 9.8) was added. The al-
caline phosphatase-dependent conversion of the sub-
strate was read at 405 nm after 45 minute incubation 
(Multiscan EX Thermo, China). Experimental data 
were statistically analyzed using software MS Excel 
and Agrometr 2.01.
Human plasma thrombin, porcine pancreas 
elastase, porcine stomach mucose pepsine and bo-
vine muscle actin were purchased from Sigma 
(USA).
results and discussion
As shown in Fig.1-3 the inhibitory effect of 
Lys-plasminogen on thrombin-induced platelet ag-
gregation is observed. In the presence of Lys-plasmi-
nogen the level of platelet aggregation is an average 
of two times lower. We have noticed that all studied 
plasminogen kringles (K1-3, K4 and K5) abolish 
the inhibitory effect of Lys-plasminogen on plate-
let aggregation at concentration 1.2 µM. However, 
we have observed that K5 is more effective than 
K1-3 and K4. The plasminogen kringle K5 added to 
the reaction mixture (washed platelets and 1.2 µM 
Lys-plasminogen) even at concentration 0.12 µM 
recovers platelet aggregation to 90%, whereas K1-3 
and K4 at this concentration reach only near 60% as 
compared with control aggregation level (Fig. 1-3). 
Besides, we have observed the tendency of slight 
stimulation of platelet aggregation in the presence of 
K5 at concentration 1.2 µм (Fig. 3). 
We have also made an attempt to answer the 
question concerning affinity of plasminogen forms 
(Glu- or Lys-plasminogen) and plasminogen frag-
ments (K1-3, K4 or mini-plasminogen, which con-
tains K5 and serine protease domain) for actin. Our 
results showed that Lys-plasminogen possessed the 
highest affinity for actin (Fig. 4, a). Glu-plasmino-
gen and plasminogen fragment K1-3 had similar IC
50
 
value, 113 and 117 nM, respectively. The binding of 
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Fig. 1. The influence of plasminogen fragment 
k1-3 on the inhibitory effect of Lys-plasminogen on 
thrombin-induced platelet aggregation: 1 – control; 
2 – 1.2 μM LysPg; 3 – 0.12 μM K1-3 + 1.2 μM LysPg; 
4 – 0.6 μM K1-3 + 1.2 μM LysPg; 5 – 1.2 μM K1-3 + 
1.2 μM LysPg. Here and below in Fig. 2–4: mean of 
three experiments (bars, SD)
Fig. 3. The influence of plasminogen fragment 
k5 on the inhibitory effect of Lys-plasminogen on 
thrombin-induced platelet aggregation: 1 – control; 
2 – 1.2 μM LysPg; 3 – 0.12 μM K5 + 1.2 μM LysPg; 
4 – 0.6 μM K5 + 1.2 μM LysPg; 5 – 1.2 μM K5 + 
1.2 μM LysPg
mini-plasminogen and K4 to actin was negligible. To 
precise IC
50
 value in case of Lys-plasminogen, the 
range of lower concentration was used (to 30 nM). 
According to the obtained data, IC
50
 value in this 
case was 1.8 nM (Fig. 4, B).
The observed effect of plasminogen kringles 
on the inhibition of platelet aggregation by Lys-plas-
minogen lets us conclude that LBS of plasminogen 
kringles provide the plasminogen binding to the ad-
hesive proteins of platelet surface. There are several 
candidates for the role of Lys-plasminogen receptors 
on the surface of activated platelets [17, 18]. These 
proteins are secreted from α-granules and remain 
bound to platelet surface. One of them is throm-
bospondin, its receptor CD47 is highly expressed 
on platelets [19]. Thrombospondin was proposed to 




















Fig. 2. The influence of plasminogen fragment 
k4 on the inhibitory effect of Lys-plasminogen on 
thrombin-induced platelet aggregation: 1 – control; 
2 – 1.2 μM LysPg; 3 – 0.12 μM K4 + 1.2 μM LysPg; 
4 – 0.6 μM K4 + 1.2 μM LysPg; 5 – 1.2 μM K4 + 
1.2 μM LysPg







































bridge platelets via binding to fibrinogen bound to 
the platelet integrin αIIbβ3 or by binding directly to 
this integrin [20]. At the same time some of throm-
bospondin repeats, TSR1 and TSR2, are considered 
as the binding sites to plasminogen [8]. Thrombos-
pondin has two binding sites for fibrinogen, one of 
which (TSR1) coincides with plasminogen binding 
site. It was suggested that the binding site of plas-
minogen to thrombospondin is located within the 
kringle 5 domain [21]. It was interesting to note 
that Lys-plasminogen binds to thrombospondin to a 
greater extent than Glu-form. At saturation throm-
bospondin bound approximately 3 times as much of 
Lys-plasminogen than Glu-plasminogen. So, we can 
suggest that in our experiments Lys-plasminogen 
can probably impede the effective binding of throm-
bospondin to fibrinogen and, as a result, the platelet 
aggregation can be less effective (see Fig. 5). The pe-
culiarity of kringle 5 which we have shown here is in 
accordance with this suggestion. On the other hand, 
actin can also be considered as a possible candidate 
for plasminogen binding. It is known that actin is ex-
posed on the platelet surface after thrombin-induced 
secretion [22]. Plasminogen is able to bind actin with 
high affinity [23]. As we can conclude from the ob-
tained results the leading role in this interaction may 
belong to plasminogen fragment K1-3.
We cannot also strike off fibrinogen from the 
list of possible candidates for plasminogen binding. 
It is known that Glu-plasminogen does not bind to 
fibrinogen in solution, and Lys-plasminogen under 
these conditions shows little affinity [24]. As it was 
found before, fibrinogen adsorbed on the surface 
undergoes conformational changes and acquires 
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Fig. 4. the binding of biotin-labeled Glu-, Lys-, mini-plasminogen (Val 442-pg) and plasminogen kringles 
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the properties of fibrin [25], which possesses good 
binding abilities to Lys-plasminogen [26]. There is 
also a possibility of immediate interaction of plas-
minogen with β2-integrins on the platelet surface. 
Activated but not resting platelets are able to express 
β2-integrins [27] and specific interaction between 
isolated K4 of plasminogen and αMβ2-integrin was 
identified in case of leucocytes [28]. The obtained data 
let us suggest that kringle 4 may play a certain role in 
the interaction of Lys-plasminogen with this integrin 
on the platelet surface. However, the role of αMβ2 in 
platelet adhesion or aggregation is still unknown. 
So, the obtained effects of plasminogen kring-
les let us conclude that LBS of plasminogen kring-
les can interact with some adhesive proteins on the 
surface of activated platelets. This interaction may 
lead to the disturbance of protein-protein interaction 
which is the necessary condition for efficient platelet 
aggregation.
Fig. 5. Fibrinogen-thrombospondin interaction in the presence of Lys-plasminogen: Fg – fibrinogen, TSP – 
thrombospondin, Lys-plg – Lys-plasminogen
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на до таких важливих процесів як тромбоутво-
рення, запалення та канцерогенез. плазміноген 
та плазмін опосередковують свою дію через 
плазміногензв’язуючі протеїни, що розташовані 
на поверхні клітин. Lys-плазміноген, на відміну 
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від Glu-форми, справляє інгібувальний вплив 
на агрегацію тромбоцитів, стимульовану аDP, 
колагеном та тромбіном в препаратах збагаченої 
тромбоцитами плазми та відмитих тромбоцитів. 
ми показали, що кринглові домени плазміногену 
забезпечують взаємодію цієї молекули з по-
верхневими протеїнами тромбоцитів. метою 
роботи було вивчення ролі окремих крингло-
вих доменів у виявленні інгібувального впливу 
Lys-плазміногену на агрегацію тромбоцитів та 
визначення можливих плазміногензв’язуючих 
протеїнів на поверхні тромбоцитів. Усі фрагмен-
ти плазміногену (K1-3, K4 і K5), що були взяті 
для дослідження, знімали інгібувальний вплив 
Lys-плазміногену на агрегацію тромбоцитів. по-
казано, що ефект K5 більш виражений порівняно 
з K1-3 та K4. препарати біотинільованих Lys-
плазміногену, Glu-плазміногену та фрагмен-
та K1-3 виявляли найбільшу афінність до 
актину, тоді як зв’язування біотинільованих міні-
плазміногену та K4 з актином було незначним. 
ми припускаємо, що інгібувальний ефект Lys-
плазміногену є наслідком взаємодії кринглових 
доменів цього протеїну з мембранозв’язаними 
протеїнами, що експонуються на поверхні тром-
боцита під час активації та залучаються до про-
цесу тромбоутворення. 
к л ю ч о в і  с л о в а: крингли плазміногену, 
агрегація тромбоцитів, плазміногенові рецепто-
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влечена в такие важные процессы как тромбо-
образование, воспаление и канцерогенез. плаз-
миноген и плазмин опосредуют свое действие 
через плазминогенсвязывающие протеины на 
поверхности клеток. Lys-плазминоген, в отли-
чие от Glu-формы, оказывает ингибирующее 
влияние на агрегацию тромбоцитов, стимули-
рованную аDP, коллагеном и тромбином в пре-
паратах обогащенной тромбоцитами плазмы и 
отмытых тромбоцитов. мы показали, что крин-
гловые домены плазминогена обеспечивают вза-
имодействие этого проэнзима с поверхностны-
ми протеинами тромбоцитов. Целью настоящей 
работы было изучить роль определенных крин-
гловых доменов в реализации ингибиторного 
эффекта Lys-плазминогена и определить воз-
можные плазминогенсвязывающие протеины 
на поверхности тромбоцитов. Все исследуемые 
фрагменты плазминогена (K1-3, K4 и K5) снима-
ли ингибирующее действие Lys-плазминогена 
на агрегацию тромбоцитов. мы обнаружили, 
что к5 обладал более выраженным эффектом 
по сравнению с K1-3 и K4. препараты биоти-
нилированных протеинов Lys-плазминогена, 
Glu-плазминогена, и фрагмента K1-3 проявляли 
наибольшее сродство к актину, в то время как 
связывание биотинилированных мини-плазми-
ногена и K4 с актином было незначительным. 
мы предполагаем, что ингибиторный эффект 
Lys-плазминогена является следствием взаимо-
действия крингловых доменов этого протеина с 
мембраносвязанными протеинами, которые экс-
понируются на поверхности тромбоцита во вре-
мя активации и вовлекаются в процесс тромбо-
образования. 
к л ю ч е в ы е  с л о в а: кринглы плазмино-
гена, агрегация тромбоцитов, плазминогеновые 
рецепторы тромбоцитов, Lys-плазминоген, актин.
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